Bryn Talkington of Requisite Capital Management named AbbVie (NYSE:ABBV) her final trade on CNBC's Halftime Report Final Trades, with a price target of $232. The mention is a modestly positive analyst-style endorsement of the healthcare stock, but it does not include new company fundamentals or operational updates.
Bryn Talkington of Requisite Capital Management named AbbVie (NYSE:ABBV) her final trade on CNBC's Halftime Report Final Trades, with a price target of $232. The mention is a modestly positive analyst-style endorsement of the healthcare stock, but it does not include new company fundamentals or operational updates.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
